Integer Holdings heads into the final day of April with short sellers quietly adding pressure and options traders the most cautious they have been all year.
The clearest tension this week is between a stock that has barely moved — down less than 2% over the past month to $83.67 — and a short position that has been grinding higher almost every session. Short interest has climbed to 11.5% of free float, up roughly 2.3% on the week and back near the top of its recent range. That is a meaningful level for a $2.85 billion mid-cap medtech name: more than one in nine freely traded shares is currently on loan to short sellers. The direction of travel has been consistently upward since late March, when shorts were clustered closer to 11.1%.
Options positioning confirms the cautious lean. The put/call ratio has jumped to 0.91 — nearly the highest reading of the past 52 weeks, against a 52-week low of just 0.10 — and roughly 1.2 standard deviations above its 20-day average of 0.66. What makes the move more notable is how abruptly it shifted: from mid-March through April 16, the PCR was running consistently below 0.50. Since April 20 it has held above 0.91 every session, a step-change that implies a meaningful rebalancing toward downside protection. The borrow market, by contrast, is not signalling a squeeze. Availability is ample: cost to borrow has eased around 16% over the past month to just 0.41% annualised, among the cheapest in the sector. There is no shortage of shares to borrow, which keeps the squeeze dynamic off the table for now.
The Street's view is mixed, with most of the meaningful analyst activity clustered around the February 20 earnings print. After that quarter, Citigroup raised its target to $92 (maintaining Neutral), Wells Fargo lifted to $84 (Equal-Weight), Benchmark upgraded to Buy with a $95 target, and Truist Securities moved to $97 while holding Buy. The mean price target has settled around $93, roughly 11% above the current price — consistent with consensus seeing modest upside but not a dramatic re-rating catalyst on the horizon. The most recent of those moves is now more than ten weeks old; there have been no material analyst changes since mid-March. EPS momentum ranks in the 66th percentile on a 90-day basis and the 86th percentile for forward year-over-year growth — that growth trajectory is what the bull case rests on. Bears counter that the company's acquisition-led model concentrates risk: a limited pool of targets and high entry prices could strain leverage and compress free cash flow.
On the institutional side, Invesco added a notable 580,340 shares as of the March 31 filing — its largest single-period addition in the data — while Manulife Asset Management picked up 442,355 shares over the same period. Those are not trivial positions for a company of this size. Irenic Capital Management, a known activist-leaning fund, reported a fresh 1.26 million share stake as of December 31. Insider activity is less instructive: the 90-day net position is technically positive in share count terms, but that largely reflects award grants offset by market sales. The CEO sold 16,945 shares at $87.10 in February — a routine post-award disposal rather than a conviction-driven exit.
Earnings context adds one more data point worth noting. The two most recent quarterly prints produced modest positive reactions: a 1.0% gain on April 23 and a 3.3% move on February 20. Neither was dramatic, but both were positive, suggesting the market has been rewarding the company's execution even against a cautious backdrop. Today, April 30, is flagged as an event date in the data — the next print or call — making the timing of the current positioning shift particularly relevant.
Among correlated peers, the week has been notably harder: LIVN dropped 9.6%, VREX fell 9.1%, and COO shed 8.3% on the week, while ITGR held its losses to under 2%. That relative resilience is worth watching — the question now is whether the options hedges and the short build reflect sector-wide caution bleeding into ITGR, or something specific to the company's own setup ahead of today's event.
See the live data behind this article on ORTEX.
Open ITGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
